Please Wait.....
Report
Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends
Company Report I 2025-05-14 I 96 Pages I Quaintel Research
Report Summary
Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends is a comprehensive and easily accessible overview of Menarini Industrie Farmaceutiche Riunite Srl 's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Menarini Industrie Farmaceutiche Riunite Srl including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Menarini Industrie Farmaceutiche Riunite Srl's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Menarini Industrie Farmaceutiche Riunite Srl's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Menarini Industrie Farmaceutiche Riunite Srl enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Menarini Group is a multinational pharmaceutical company that operates in the healthcare industry. The company offers a wide range of products and services, including prescription drugs, over-the-counter medications, medical devices, and diagnostic tests. They specialize in various therapeutic areas such as cardiovascular, respiratory, gastroenterology, and oncology. Menarini also provides services in the areas of clinical research, drug development, and manufacturing.
In addition, the company offers educational programs and resources for healthcare professionals and patients. Menarini is committed to improving the health and well-being of individuals worldwide through their innovative and high-quality products and services. Founded in 1886, the company is headquartered in Firenze, Toscana, Italy.
Menarini Industrie Farmaceutiche Riunite Srl in the News:-
- 20-Mar-2025 - Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- 10-Feb-2025 - Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
- 11-Dec-2024 - Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cance
- 03-Dec-2024 - A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System
- 30-Nov-2024 - Fair Play Menarini - The Champions Tell their Stories: tales of sport and life triumph at the talk show
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Menarini Industrie Farmaceutiche Riunite Srl's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Menarini Industrie Farmaceutiche Riunite Srl:
- Menarini Industrie Farmaceutiche Riunite Srl PESTLE Analysis
- Menarini Industrie Farmaceutiche Riunite Srl Value Chain Analysis
- Menarini Industrie Farmaceutiche Riunite Srl Porter's Five Forces Analysis
- Menarini Industrie Farmaceutiche Riunite Srl VRIO Analysis
- Menarini Industrie Farmaceutiche Riunite Srl BCG Analysis
- Menarini Industrie Farmaceutiche Riunite Srl Segmentation, Targeting and Positioning (STP) Analysis
- Menarini Industrie Farmaceutiche Riunite Srl Ansoff Matrix Analysis
Table of Contents
Table of Contents 2
Tables 5
Charts 6
Menarini Industrie Farmaceutiche Riunite Srl - Key Company Facts 7
Menarini Industrie Farmaceutiche Riunite Srl - Company Description 8
Menarini Industrie Farmaceutiche Riunite Srl - Top Executives 9
Menarini Industrie Farmaceutiche Riunite Srl - Head Office & Locations 10
Head Office - Country 10
Key Subsidiaries 11
Menarini Industrie Farmaceutiche Riunite Srl - Products and Services 12
Products 12
Services 14
Menarini Industrie Farmaceutiche Riunite Srl - Historic Events 16
Menarini Industrie Farmaceutiche Riunite Srl - Corporate Strategy 17
Menarini Industrie Farmaceutiche Riunite Srl - Business Description 20
Pharmaceuticals 20
Diagnostics 21
International Segment 21
Italy Segment 22
Other Segment 22
Menarini Industrie Farmaceutiche Riunite Srl - ESG Spotlight 23
Environment 23
Social 24
Corporate Governance 24
Menarini Industrie Farmaceutiche Riunite Srl - SWOT Analysis 25
Overview 25
Strengths 27
Weaknesses 29
Opportunities 30
Threats 32
Competing Players 34
Snapshot of Competing Players 35
Novartis AG 35
Key Company Facts 35
Company Description 35
Novartis AG - SWOT Spotlight 36
Key Financials 38
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 38
Key Financial Ratio Analysis 43
Pfizer Inc. 44
Key Company Facts 44
Company Description 44
Pfizer Inc. - SWOT Spotlight 45
Pfizer Inc. - PESTLE Spotlight 47
Key Financials 49
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 49
Key Financial Ratio Analysis 54
Sanofi S.A. 55
Key Company Facts 55
Company Description 55
Sanofi S.A. - SWOT Spotlight 56
Sanofi S.A. - PESTLE Spotlight 58
Key Financials 60
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 60
Key Financial Ratio Analysis 65
F. Hoffmann-La Roche Ltd 66
Key Company Facts 66
Company Description 66
GlaxoSmithKline Pharmaceuticals Ltd 67
Key Company Facts 67
Company Description 67
Key Financials 68
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 68
Key Financial Ratio Analysis 73
Menarini Industrie Farmaceutiche Riunite Srl - In the News 74
20-Mar-2025 - Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 74
10-Feb-2025 - Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology 76
11-Dec-2024 - Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cance 78
03-Dec-2024 - A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System 80
30-Nov-2024 - Fair Play Menarini - The Champions Tell their Stories: tales of sport and life triumph at the talk show 80
26-Nov-2024 - Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC) 83
20-Nov-2024 - Fair Play Menarini: the names of the participants at The Champions Tell their Stories talk show are revealed 85
08-Nov-2024 - Sport and Social Commitment: the path of the Volpi Rosse Menarini continues 87
15-Oct-2024 - Fair Play Menarini International Award, save the date for the talk show The Champions Tell Their Stories 88
29-Jul-2024 - Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia 89
Menarini Industrie Farmaceutiche Riunite Srl - Key Deals 92
09-Jan-2024 - Menu Close 2024 - 1 - 9 Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries 92
Appendix 93
Definitions 93
SWOT Analysis 93
PESTLE Analysis 93
Value Chain Analysis 93
ESG Spotlight 93
Research Methodology 94
Disclaimer 95
Contact Us 95
Tables
Table 1: Menarini Industrie Farmaceutiche Riunite Srl - Company Facts
Table 2: Menarini Industrie Farmaceutiche Riunite Srl - Digital Presence
Table 3: Menarini Industrie Farmaceutiche Riunite Srl - Top Executives
Table 4: Menarini Industrie Farmaceutiche Riunite Srl - Subsidiaries
Table 5: Menarini Industrie Farmaceutiche Riunite Srl - Products
Table 6: Menarini Industrie Farmaceutiche Riunite Srl - Services
Table 7: Menarini Industrie Farmaceutiche Riunite Srl - Historic Events
Table 8: Menarini Industrie Farmaceutiche Riunite Srl - Competing Players
Table 9: Competing Players - Novartis AG - Key Company Facts
Table 10: Novartis AG - Share Price Trend - Jan-2024 to May-2025
Table 11: Competing Players - Novartis AG - Profit and Loss Statement
Table 12: Novartis AG - Balance Sheet 2021-2024
Table 13: Novartis AG - Cash Flow Statement 2021-2024
Table 14: Novartis AG - Ratio Analysis - 2021-2024
Table 15: Competing Players - Pfizer Inc. - Key Company Facts
Table 16: Pfizer Inc. - Share Price Trend - Jan-2024 to May-2025
Table 17: Competing Players - Pfizer Inc. - Profit and Loss Statement
Table 18: Pfizer Inc. - Balance Sheet 2021-2024
Table 19: Pfizer Inc. - Cash Flow Statement 2021-2024
Table 20: Pfizer Inc. - Ratio Analysis - 2021-2024
Table 21: Competing Players - Sanofi S.A. - Key Company Facts
Table 22: Sanofi S.A. - Share Price Trend - Jan-2024 to May-2025
Table 23: Competing Players - Sanofi S.A. - Profit and Loss Statement
Table 24: Sanofi S.A. - Balance Sheet 2021-2024
Table 25: Sanofi S.A. - Cash Flow Statement 2021-2024
Table 26: Sanofi S.A. - Ratio Analysis - 2021-2024
Table 27: Competing Players - F. Hoffmann-La Roche Ltd - Key Company Facts
Table 28: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Company Facts
Table 29: GlaxoSmithKline Pharmaceuticals Ltd - Share Price Trend - Jan-2024 to May-2025
Table 30: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Profit and Loss Statement
Table 31: GlaxoSmithKline Pharmaceuticals Ltd - Balance Sheet 2021-2024
Table 32: GlaxoSmithKline Pharmaceuticals Ltd - Cash Flow Statement 2021-2024
Table 33: GlaxoSmithKline Pharmaceuticals Ltd - Ratio Analysis - 2021-2024
Charts
Figure 1: Menarini Industrie Farmaceutiche Riunite Srl - SWOT Analysis
Figure 2: Competing Players - Novartis AG - SWOT Spotlight
Figure 3: Novartis AG - Average Share Price Trend - Jan-2024 to May-2025
Figure 4: Novartis AG - Profit and Loss Statement - 2021-2024
Figure 5: Novartis AG - Balance Sheet - 2021-2024
Figure 6: Novartis AG - Cash Flow Statement 2021-2024
Figure 7: Competing Players - Pfizer Inc. - SWOT Spotlight
Figure 8: Competing Players - Pfizer Inc. - PESTLE Spotlight
Figure 9: Pfizer Inc. - Average Share Price Trend - Jan-2024 to May-2025
Figure 10: Pfizer Inc. - Profit and Loss Statement - 2021-2024
Figure 11: Pfizer Inc. - Balance Sheet - 2021-2024
Figure 12: Pfizer Inc. - Cash Flow Statement 2021-2024
Figure 13: Competing Players - Sanofi S.A. - SWOT Spotlight
Figure 14: Competing Players - Sanofi S.A. - PESTLE Spotlight
Figure 15: Sanofi S.A. - Average Share Price Trend - Jan-2024 to May-2025
Figure 16: Sanofi S.A. - Profit and Loss Statement - 2021-2024
Figure 17: Sanofi S.A. - Balance Sheet - 2021-2024
Figure 18: Sanofi S.A. - Cash Flow Statement 2021-2024
Figure 19: GlaxoSmithKline Pharmaceuticals Ltd - Average Share Price Trend - Jan-2024 to May-2025
Figure 20: GlaxoSmithKline Pharmaceuticals Ltd - Profit and Loss Statement - 2021-2024
Figure 21: GlaxoSmithKline Pharmaceuticals Ltd - Balance Sheet - 2021-2024
Figure 22: GlaxoSmithKline Pharmaceuticals Ltd - Cash Flow Statement 2021-2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security